Shanghai2023/11/4 /PRNewswire/ -- Recently, Siemens Healthcare, the world's leading medical technology company, participated in the China International Import Expo (hereinafter referred to as the “Expo”) six times under the theme of “Innovation World, for Every Life”. As a “fan” who has never been absent, Siemens Healthcare will present a panoramic view of more than 20 cutting-edge innovative medical technologies and solutions in the “Medical Devices and Healthcare Exhibition Area” this year. Tao Lin, a member of the board of directors of Siemens Healthcare, said, “The Expo is an important initiative for China to promote a high level of opening-up to the outside world in the new era. It is also an excellent stage for enterprises to showcase their innovative strength and broaden development opportunities. “Checking in” for the sixth year in a row has not only demonstrated Siemens Healthcare's firm confidence in the Chinese market, but also our determination to continue to accelerate the integration of the latest global technological achievements and local cutting-edge wisdom, and continue to deepen cooperation with our partners to meet the most urgent medical needs of Chinese patients and serve the Chinese medical industry.”
The launch of major new products is concentrated, leading a new era of accurate diagnosis and treatment of major diseases
At this expo, Siemens Healthcare brought a variety of revolutionary new products with “first launches”, empowering accurate diagnosis and treatment of tumors and cardiovascular and cerebrovascular diseases through breakthrough innovation.
- Siemens Healthcare's world's first ultra-powerful full-body 3Tmagnetic resonance MAGNETOM Cima.X[1]The introduction of a breakthrough “Gemini” gradient system enhances full-body clinical imaging performance to an unprecedented 200 mT/m maximum gradient field strength and 200 T/m/s maximum gradient switching rate. Compared with conventional clinical 3T magnetic resonance, its gradient performance has increased four to five times, setting a new standard for top-level scientific magnetic resonance. In the field of oncology, the device will help users to measure pathological-grade cell morphology and density, greatly improving the accuracy of the qualitative and grading of early tumors; in the neurological field, the device can study brain microstructures such as neuronal axons, which is expected to further clarify the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's syndrome, and help brain science research enter the mesoscopic microscale.
- Siemens Healthcare's world's first “walking” CT SOMATOM On.site[2]It is small in size and lightweight, and can be pushed into wards and operating rooms at will, so patients can receive CT scans of the head at the bedside. Compared with CT scans performed by traditional transfer radiology departments, the application of SOMATOM ON.site can save about 75% of transit time, effectively avoid delays or secondary damage caused by transportation, and will greatly improve the efficiency and effectiveness of first aid for patients with severe illnesses such as stroke, traumatic brain injury, and brain tumors. Its original radiation-proof nutshell rack and lead curtain can achieve double radiation protection to ensure that doctors and patients are not bothered by radiation problems throughout the examination process. In addition, SOMATOM ON.site can also provide accurate intraoperative navigation, enabling doctors to quickly rescue patients with severe brain injuries and multiple injuries.
- The best 178 in historypicosecond TOFSuper performance PET/CT Biograph Vision.X[3]Breaking through industry limits and achieving 170 picosecond temporal resolution for the first time, it can bring 7.5 times clinical performance gain. TOF technology is the core technology of PET/CT. Its performance is critical to the image accuracy, acquisition speed, and dosage of PET/CT imaging. For patients with advanced cancer metastases or patients who are unable to perform surgery, integrated nuclide diagnosis and treatment can bring them a glimmer of life. In the era of integrated nuclide diagnosis and treatment, the clinical value of 178-picosecond TOF PET/CT extends throughout the entire tumor life cycle from disease diagnosis, patient screening, post-operative verification, and efficacy evaluation to follow-up, and will bring more accurate new cancer diagnosis and treatment plans for patients with advanced and difficult tumors.
- The new four-dimensional volumetric intracardiac ultrasound catheter is leading the transformation of structural heart disease intervention procedures.ACUSON AcuNav Volume 4D ICE Catheter[4]It is a pioneering innovative device in the field of structural heart disease. With advantages such as zero radiation, no need for total anesthesia, and visualization, doctors can be guided to perform interventional treatments such as valve repair and replacement or left ventricular occlusion to help doctors monitor the entire operation in real time, reduce complications, and improve the success rate and efficiency of surgery. It is expected to become the best guidance tool for structural heart disease interventional procedures. Today, with the rapid development of interventional treatment for structural heart disease, this technology has very broad application prospects.
- ARTIS Icono ceiling, the world's first quantum spectroscopic angiography system[5]Based on innovation, many breakthroughs have been achieved in clinical applications: breaking through the limitations of traditional equipment in “time and space”, so that patients can perform 3D scanning and reconstruction of the whole body during free breathing; improving accuracy to submillimeter levels to protect the refined treatment of tumors; reconstructing the image chain based on big data and artificial intelligence to ensure clear and constant images, while intelligently adjusting the X-ray spectrum effectively reduces radiation levels and leads a new era of accurate cancer treatment.
Drive the high-quality development of medical technology by taking advantage of the “East Wind in the Expo”
The CIIE is a display platform for enterprise innovation, and a powerful engine for accelerating the implementation of innovative achievements. Over the past six years, the “spillover effects” released by the Expo and continued to expand have turned many Siemens Healthcare exhibits into products, and products have exploded. Take NAEOTOM Alpha, the world's first photon counting CT, as an example. The semiconductor detector photon counting CT technology made a simultaneous global debut at the 4th Expo in 2021. The following year, NAEOTOM Alpha entered the National Drug Administration's Special Examination Program for Medical Devices (Green Innovation Channel), and completed the first physical machine exhibition in Asia at the 5th Expo 2022. At present, NAEOTOM Alpha has completed domestic testing at Peking Union Medical College Hospital and Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and was officially approved for listing in China by the National Drug Administration (NMPA) in mid-October 2023. At the 6th CIIE, Siemens Healthcare will also fully showcase NAEOTOM Alpha's extensive clinical application and scientific research results.
Wang Hao, president of Siemens Healthcare Greater China, said, “The Expo is a window for China to construct a new development pattern, and has also injected strong momentum into the innovation and development of the medical industry. Siemens Healthcare will continue to increase its participation in China's cutting-edge clinical research and primary health care system as many global innovations accelerate their launch and implementation in China through the Expo, and as local partnerships continue to deepen. In the future, we will actively work with our partners to promote the construction of an innovation ecosystem in China and contribute to the high-quality development of medical technology in China and the construction of a 'healthy China'.”
[1] MAGNETOM Cima.x is still in the FDA registration process |
[2] SOMATOM on.site is still in the FDA registration process |
[3] Biograph vision.x was approved by the FDA in July 2023 and is still in the NMPA registration process |
[4]ACUSON Acunav Volume 4D ICE Catheters have received CE marking and FDA approval |
[5]ARTIS Icono ceiling was approved by the FDA in July 2022 and is still in the NMPA registration process |
About Siemens Healthcare
Siemens Healthcare (Frankfurt Stock Exchange: SHL), based in Erlangen, Germany, is a leading medical technology company committed to continuously developing a portfolio of products and services, including AI-based applications and digital products that play an increasingly important role in the development of next-generation medical technology. These new applications will further strengthen the company's foundation in the fields of in vitro diagnosis, image-guided treatment, in vivo diagnosis, and novel cancer diagnosis and treatment. At the same time, Siemens Healthcare provides a wide range of services and solutions to help medical service providers improve their capabilities and provide high-quality and efficient services to patients. In fiscal year 2022 (ending September 30, 2022), Siemens Healthcare's total revenue was €21.7 billion and has approximately 69,500 employees worldwide.